Welcome to our dedicated page for Bio Green Med Solution news (Ticker: BGMS), a resource for investors and traders seeking the latest updates and insights on Bio Green Med Solution stock.
Bio Green Med Solution, Inc. reports news about its transition from the former Cyclacel Pharmaceuticals business to a company focused on fire safety protection and distribution activities. The company completed the acquisition of Fitters Sdn. Bhd., a Malaysia-based fire safety materials and equipment business, and reports product revenue from sales and distribution of fire safety equipment.
Company updates also cover quarterly and annual financial results, the liquidation of its former U.K. subsidiary, the sale of its Plogosertib drug, cash position commentary, and business updates tied to its current fire protection products and services focus.
ARC Group Acquisition I Corp (ARCL) agreed to acquire 100% of Firstborn Top Capital Sdn. Bhd., valuing the Malaysian private financing company at an implied pro forma enterprise value of approximately $1,091.2 million, with closing expected in the first quarter of 2027.
Firstborn Top Capital will become a wholly owned subsidiary of ARCL, and the combined company will be renamed BlueCrest Investment, Inc. and is expected to trade on the Nasdaq Global Market under the ticker BCIN. The valuation assumes ARCL raises $5 million in PIPE financing and that its $120.8 million trust experiences 0% redemptions. At closing, existing Firstborn Top Capital shareholders are expected to own approximately 82.39% of the combined company, while public investors are expected to hold about 12.4%. Proceeds are intended for market expansion, lending infrastructure development, and marketing capabilities. Boards of both companies have approved the deal, which remains subject to ARCL shareholder approval and customary conditions.
Bio Green Med Solution (NASDAQ: BGMS) reported second quarter 2026 results and strategic updates. Fire safety product revenue for the quarter ended June 30, 2026 was $336,000, generating cost of sales of $257,000 and a gross margin of approximately 23%. Net loss from continuing operations narrowed to $405,000 from $1.25 million in the prior-year period, primarily driven by a reduction in general and administrative expenses to $497,000 from $1.249 million.
Cash and cash equivalents were $3.8 million at June 30, 2026, up from $3.5 million at December 31, 2025, and the company estimates current resources will fund planned expenditure into the first quarter of 2027. BGMS entered into a Business Combination Agreement with Future NRG, under which Future NRG shareholders are expected to own more than 99% of the combined company after closing, subject to conditions. The company also signed a Securities Purchase Agreement for 1,103,338 common shares at $0.72 per share, for gross proceeds of approximately $794,403, and declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, paid August 1, 2026.
Bio Green Med Solution (NASDAQ: BGMS) signed a Business Combination Agreement to acquire Future NRG Sdn. Bhd. in an all‑stock share exchange. Future NRG will become a wholly owned subsidiary, and the combined company will keep the Bio Green Med Solution name and BGMS ticker.
The deal targets healthcare clinical waste-to-energy markets and integrated fire safety solutions, creating a bundled compliance offering. Existing BGMS leadership, led by CEO Datuk Dr. Doris Wong, will continue, with one board change. Closing is expected in Q4 2026, subject to shareholder and regulatory approvals.
Bio Green Med Solution (NASDAQ: BGMS) reported Q1 2026 results and business updates. The company, now focused on fire safety protection and distribution, generated $0.8 million in fire safety product revenue and reported a net loss of $0.2 million.
Cash and cash equivalents were $3.3 million at March 31, 2026, with operating cash use of $0.3 million. General and administrative expenses fell to $0.4 million from $4.2 million a year earlier. Trading of its 6% Convertible Exchangeable Preferred Stock (BGMSP) was suspended and delisted, while a $0.15 quarterly dividend on BGMSP was paid May 1, 2026.
Bio Green Med Solution (NASDAQ: BGMS) reported Q4 and full-year 2025 results, highlighting the Sept 12, 2025 acquisition of Fitters, sale of plogosertib for $300,000 plus a potential $170,000 milestone, and liquidation of its U.K. subsidiary.
As of Dec 31, 2025 cash totaled $3.5M, product revenue from fire-safety sales was $0.7M, net loss for 2025 was $3.0M, and the company estimates cash runway into Q3 2026.
Bio Green Med Solution (NASDAQ: BGMS) reported Q3 results for the period ended September 30, 2025 and provided a business update.
Key facts: cash and cash equivalents of $3.8M (up from $3.1M at 12/31/24); estimated cash runway into the first quarter of 2026; net loss of $1.0M for Q3 2025 versus $2.0M a year earlier; product revenue from fire safety sales of $81k and cost of sales of $64k following the September acquisition of Fitters Sdn. Bhd.; R&D expense of $0 in Q3 2025 after liquidation of the UK subsidiary.
Corporate actions: a 1-for-15 reverse stock split effective July 7, 2025; sale of Plogosertib-related patents for $300k plus up to $170k in potential milestone payments; Fitters exchange resulted in Fitters owning approximately 19.99% of BGMS; two warrant exchange transactions converted warrants into an aggregate of 1,962,000 new shares.